Predictors of adherence to treatment of chronic hepatitis C in drug-dependent inmate patients in four prisons in Barcelona, Spain;Factores predictivos de cumplimiento deltratamiento de lahepatitis c crónica en personas drogodependientes de cuatro prisiones de Barcelona

Revista Espanola de Salud Publica

Volumn 84, Issue 4, 2010, Pages 421-429

  Mouriño, Andrés Marco ^a   Da Silva Morán, Antonio ^a   Seuma, Jordi Ortiz ^b   Carbó, Concepció Solé ^c   Alemany, Mercè Roget ^b   Gracia, Carmen Sarriera ^a   Pérez, Núria Teixidó ^c   Guillén, Pilar Robres ^a   Moreno, Rafael Alonso Guerrero ^d  

^a Servicios Médicos Penitenciarios ^*  (Spain)

^b Terrassa   (Spain)

^c Servicios Médicos Penitenciarios de Brians i   (Spain)

^d GENERALITAT DE CATALUNYA   (Spain)

Author keywords

Cessation of treatment; Hepatitis C; Intravenous; Prisons; Substance abuse

Indexed keywords

ADDICTION; ARTICLE; HEPATITIS C; HUMAN; PATIENT COMPLIANCE; PRISONER; PROGNOSIS; QUESTIONNAIRE; SPAIN; TREATMENT OUTCOME;

HEPATITIS C, CHRONIC; HUMANS; MEDICATION ADHERENCE; PRISONERS; PROGNOSIS; QUESTIONNAIRES; SPAIN; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 78650636293     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, et al: Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006;101: 1499-508.
2. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, et al: Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007; 21(Suppl 8):S39-46.
3. Micallef JM, Macdonald V, Jauncey M, Amin J, Rawlinson W, van Beek I, et al: High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat. 2007; 14:413-8.
4. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al: High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology. 2008; 48:1746-52.
5. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, et al: HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy. 2007; 18:341-51.
6. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C.: Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008; 168:1099-109.
7. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al: Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend. 2007; 91:228-35.
8. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Aust N Z J Public Health. 2004; 28:576-8.
9. Macías J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008; 28:781-6.
10. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, et al: Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend. 2005; 79:389-95.
11. Koblin BA, Factor SH, Wu Y, Vlahov D. Hepatitis C virus infection among noninjecting drug users in New York City. J Med Virol. 2003; 70:387-90.
12. Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC: Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007; 195:1052-61.
13. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD: Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003; 138:187-90.
14. Grupo del Noroeste para el estudio de la Hepatitis por Virus C en el medio penitenciario. Seroprevalencia de infección por virus C de la hepatitis en población reclusa del noroeste de España a su ingreso en prisión. Rev Esp Salud Pública. 1998; 72:43-51
15. Añón C, Del Olmo JA, Llovet F, Serra MA, Gilabert S, Rodríguez F, et al. Virus C de la hepatitis entre población penitenciaria de Valencia. Rev Esp Enferm Dig. 1995; 87:505-8.
16. Pallás JR, Farinas-Álvarez C, Prieto D, Delgado-Rodríguez M. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol. 1999; 15:699-704.
17. Saiz de la Hoya P, Bedia M, Murcia J. Cebriá J, Sánchez-Paya J, Portilla J. Factores predictivos de infección por el VIH, VHC y coinfección en la población reclusa de una prisión española. Enferm Infecc Microbiol Clin. 2005; 23: 53-57.
18. de la Hoya-Saiz P, Marco A, García-Guerrero J, Mallo AJ, Faraco I, Quiñonero J, et al. Prevalence of hepatitis C virus infection among spanish prisoners. Madrid: OMS, Prison Health Conference; 2009 (abstract 56).
19. Bruguera M, Forns X. Hepatitis C en España. Med Clin (Barc). 2006; 127:113-7.
20. Martín-Sánchez V, Marco A, Saiz de la Hoya P. Cómo combatir la hepatitis C en las cárceles. Gastroenterol Hepatol. 2005; 28(Supl 3):37-40.
21. Strock P, Mossong J, Hawotte K, Arendt V: Access to Treatment of Hepatitis C in Prison Inmates. Dig Dis Sci. 2009; 54:1325-30.
22. McGovern B, Fiore J, Wurcel A, Taglienti P, Bradley M, Galvin S, et al: Delivering therapy for hepatitis C virus infection to incarcerated HIV-seropositive patients. Clin Infect Dis. 2005; 41(Suppl 1): S56-62.
23. Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003; 52:1500-4.
24. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al: A framework for management of hepatitis C in prisons. Ann Intern Med. 2006; 144:762-9.
25. Maru DS, Bruce RD, Basu S, Altice FL: Clinical outcomes of hepatitis C treatment in a prison set-ting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008; 47:952-61.
26. Tan JA, Joseph TA, Saab S: Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48:1387-95.
27. Saiz de la Hoya-Zamácola P, Marco-Mouriño A, Clemente-Ricote G, Portilla-Sogorb J, Boix-Martínez V, Núñez- Martínez O, et al: Expert recommendations for the diagnosis and treatment of chronic hepatitis C infection in the prison setting. Gastroenterol Hepatol. 2006; 29:551-9.
28. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, Vidaud M, et al. Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. GUT. 2003; 52: 900-2.
29. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology. 2001; 3: 188-193.
30. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al: Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat. 2008;15:747-52.
31. Grebely J, Raffa JD, Meagher C, Duncan F, Genoway KA, Khara M, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol. 2007; 22: 1519-25.
32. Butler T, Kariminia A, Levy M, Kaldor J: Prisoners are at risk for hepatitis C transmission. Eur J Epidemiol. 2004;19:1119-22.
33. Hellard ME, Hocking JS, Crofts N: The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect. 2004;132:409-15.
34. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J: Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16:1043-9.
35. Miller ER, Bi P, Ryan P: Hepatitis C virus infection in South Australian prisoners: seroprevalence, seroconversion, and risk factors. Int J Infect Dis. 2009;13:201-8.
36. O'Sullivan BG, Levy MH, Dolan KA, Post JJ, Barton SG, Dwyer DE, et al: Hepatitis C transmission and HIV post-exposure prophylaxis after needleand syringe-sharing in Australian prisons. Med J Aust. 2003; 178:546-9.
37. Krook AL, Stokka D, Heger B, Nygaard E: Hepatitis C treatment of opioid dependants receiving maintenance treatment: results of a Norwegian pilot study. Eur Addict Res. 2007;13: 216-21.
38. Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al: Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18:437-43.
39. Nguyen OK, Dore GJ, Kaldor JM, Hellard ME: Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy. 2007;18: 447-51.
40. Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA: Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005; 95:1737-9.
41. Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007; 19:741-7.
42. Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al: Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/ buprenorphine maintenance therapy. Dig Liver Dis. 2009; 41: 303-7.
43. Grebely J, de Vlaming S, Duncan F, Viljoen M, Conway B: Current approaches to HCV infection in current and former injection drug users. J Addict Dis. 2008; 27:25-35.
44. Alvarez-Uria G, Day JN, Nasir AJ, Rusell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int. 2009: 29: 1051-5.
45. Jhon-Baptiste A, Varenbut M, Lingley M, Nedd-Roderique T, Teplin D, Tomlinson G, et al. Treatment of hepatitis C infection for current of former substance abusers in a community setting. J Viral Hepat. 2009; 16: 557-67.
46. Robaeys G, Van Vlierberghe H, Matheï C, Van Ranst M, Bruckers L, Buntinx F, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol. 2006; 18:159-66.